来自专业的译者、企业、网页和免费的翻译库。
summary of resources 4.1 .
summary of resources 4.1 .
最后更新: 2011-10-23
使用频率: 1
质量:
note for guidance on summary of requirements for active substances in part ii of the dossier
note for guidance on summary of requirements for active substances in part ii of the dossier
最后更新: 2011-10-23
使用频率: 1
质量:
警告:此对齐可能有误。
如果您觉得是这样,请将其删除。
titel på dokumentet antimicrobials for veterinary use summary of product characteristics for antimicrobial products ectoparasiticide guidance for sheep, cattle and goats fluid therapy
asiakirjan nimi antimicrobials for veterinary use summary of product characteristics for antimicrobial products ectoparasiticide guidance for sheep, cattle and goats fluid therapy
最后更新: 2011-10-23
使用频率: 1
质量:
警告:此对齐可能有误。
如果您觉得是这样,请将其删除。
titel på dokumentet antimicrobials for general use in target animal species summary of product characteristics for antimicrobial products efficacy requirements for ectoparasiticides for cattle fluid therapy
asiakirjan nimi antimicrobials for general use in target animal species summary of product characteristics for antimicrobial products efficacy requirements for ectoparasiticides for cattle fluid therapy
最后更新: 2011-10-23
使用频率: 1
质量:
警告:此对齐可能有误。
如果您觉得是这样,请将其删除。
prospective planning of pharmacovigilance notice to applicants – guideline on the summary of product characteristics (ec december 1999 – revised version)
prospective planning of pharmacovigilance notice to applicants – guideline on the summary of product characteristics (ec december 1999 – revised version)
最后更新: 2011-10-23
使用频率: 1
质量:
警告:此对齐可能有误。
如果您觉得是这样,请将其删除。
summary of questions and options - annex to the interim report on the european monetary system - ( heyveart report no. 39 )
summary of questions and options - annex to the interim report on the european monetary system - ( heyveart report no. 39 )
最后更新: 2011-10-23
使用频率: 1
质量:
grundlag af den forelagte dokumentation, den faglige drøftelse i udvalget og den foreslåede ordlyd i den ajourførte udgave af guideline on summary of product characteristics fra oktober 2005 og den seneste qrd- model,
2005
最后更新: 2011-10-23
使用频率: 1
质量:
警告:此对齐可能有误。
如果您觉得是这样,请将其删除。
på grund af den betydning, som adækvat smertebehandling af moderen må tillægges, kan chmp i overensstemmelse med "guideline on summary of product characteristics" tilslutte sig, at den forslåede tekst forbliver i pkt.
tämä tarkoittaa, että valmistetta voidaan antaa imettäville äideille, mutta imetys on keskeytettävä fentanyylilaastareiden käytön ajaksi, ja imetystä saa jatkaa aikaisintaan 72 tuntia laastarin poistamisen jälkeen.
最后更新: 2012-04-12
使用频率: 2
质量:
警告:包含不可见的HTML格式
grundlag af den forelagte dokumentation, den faglige drøftelse i udvalget og den foreslåede ordlyd i den ajourførte udgave af guideline on summary of product characteristics fra oktober 2005 og de seneste qrd- modeller (version 7),
2005
最后更新: 2011-10-23
使用频率: 1
质量:
警告:此对齐可能有误。
如果您觉得是这样,请将其删除。
core summary of product characteristics for hepatitis b immunoglobulin revision of core summary of product characteristics for human normal immunoglobulin for intravenous use – addition of indication for treatment of parvovirus b19 infection revision of core summary of product characteristics for human plasma derived factor vii products and human plasma prothrombin complex revision of core summary of product characteristics for factor viii inhibitor bypassing fraction warning on transmissible agents for patient leaflets and summary of product characteristics revision of core summary of product characteristics for human anti- d immunoglobulin for intravenous and/ or intramuscular use (cpmp/ bpwg/ 574/ 99)
core summary of product characteristics for hepatitis b immunoglobulin revision of core summary of product characteristics for human normal immunoglobulin for intravenous use – addition of indication for treatment of parvovirus b19 infection revision of core summary of product characteristics for human plasma derived factor vii products and human plasma prothrombin complex revision of core summary of product characteristics for factor viii inhibitor bypassing fraction warning on transmissible agents for patient leaflets and summary of product characteristics revision of core summary of product characteristics for human anti- d immunoglobulin for intravenous and/ or intramuscular
最后更新: 2011-10-23
使用频率: 1
质量:
警告:此对齐可能有误。
如果您觉得是这样,请将其删除。